ZinmanB, WannerC, LachinJM, et al.EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015; [Epub ahead of print: DOI: 10.1056/NEJMoa1504720.
2.
MeekTH, DorfmanMD, MatsenME, et al.Evidence that in uncontrolled diabetes, hyperglucagonemia is required for ketosis but not for increased hepatic glucose production or hyperglycemia. Diabetes, 2015; 64:2376–2387.
3.
BonnerC, Kerr-ConteJ, GmyrV, et al.Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med, 2015; 21:512–517.
